The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Open accessAbstract
Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during human development and reproduction; however, aberrant regulation of angiogenesis is also a fundamental process found in several pathologic conditions, including cancer. As a process required for invasion and metastasis, tumor angiogenesis constitutes an important point of control of cancer progression. Although not yet completely understood, the complex process of tumor angiogenesis involves highly regulated orchestration of multiple signaling pathways. The proangiogenic signaling molecule vascular endothelial growth factor (VEGF) and its cognate receptor (VEGF receptor 2 [VEGFR-2]) play a central role in angiogenesis and often are highly expressed in human cancers, and initial clinical efforts to develop antiangiogenic treatments focused largely on inhibiting VEGF/VEGFR signaling. Such approaches, however, often lead to transient responses and further disease progression because angiogenesis is regulated by multiple pathways that are able to compensate for each other when single pathways are inhibited. The platelet-derived growth factor (PDGF) and PDGF receptor (PDGFR) and fibroblast growth factor (FGF) and FGF receptor (FGFR) pathways, for example, provide potential escape mechanisms from anti-VEGF/VEGFR therapy that could facilitate resumption of tumor growth. Accordingly, more recent treatments have focused on inhibiting multiple signaling pathways simultaneously. This comprehensive review discusses the limitations of inhibiting VEGF signaling alone as an antiangiogenic strategy, the importance of other angiogenic pathways including PDGF/PDGFR and FGF/FGFR, and the novel current and emerging agents that target multiple angiogenic pathways for the treatment of advanced solid tumors. Implications for Practice: Significant advances in cancer treatment have been achieved with the development of antiangiogenic agents, the majority of which have focused on inhibition of the vascular endothelial growth factor (VEGF) pathway. VEGF targeting alone, however, has not proven to be as efficacious as originally hoped, and it is increasingly clear that there are many interconnected and compensatory pathways that can overcome VEGF-targeted inhibition of angiogenesis. Maximizing the potential of antiangiogenic therapy is likely to require a broader therapeutic approach using a new generation of multitargeted antiangiogenic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
Lymphangiogenesis: Molecular Mechanisms and Future Promise
Tammela, T., & Alitalo, K. (2010) · Cell · doi:10.1016/j.cell.2010.01.045 · Cited by 1,441
Demetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., Negrier, S., Chevreau, C., Desai, A. A., Rolland, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5511 · Cited by 1,085
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., Oudard, S., Gore, M. E., Tarazi, J., Hariharan, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70093-7 · Cited by 745
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
Adverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560
Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Targeting the PDGF signaling pathway in tumor treatment
Heldin, C.-H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 540
Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., & Asada, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5270 · Cited by 530
PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis
Cao, R., Björndahl, M. A., Religa, P., Clasper, S., Garvin, S., Galter, D., Meister, B., Ikomi, F., Tritsaris, K., Dissing, S., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.034 · Cited by 527
RET revisited: expanding the oncogenic portfolio
Mulligan, L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3680 · Cited by 513
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Targeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2894 · Cited by 468
Chang, Y. S., Adnane, J., Trail, P. A., Levy, J., Henderson, A., Xue, D., Bortolon, E., Ichetovkin, M., Chen, C., McNabola, A., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0393-4 · Cited by 459
Sternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
The discovery of placenta growth factor and its biological activity
De Falco, S. (2012) · Experimental and Molecular Medicine · doi:10.3858/emm.2012.44.1.025 · Cited by 425
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Loges, S., Mazzone, M., Hohensinner, P., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 393
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Ring, L., New, T., Zabski, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398399 · Cited by 312
Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family
Tischer, E., Gospodarowicz, D., Mitchell, R., Silva, M., Schilling, J., Lau, K., Crisp, T., Fiddes, J. C., & Abraham, J. A. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92729-0 · Cited by 311
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Cao, Y. (2009) · Science Signaling · doi:10.1126/scisignal.259re1 · Cited by 289
Abou-Elkacem, L., Arns, S., Brix, G., Gremse, F., Zopf, D., Kiessling, F., & Lederle, W. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1162 · Cited by 282
The role of fibroblast growth factors in vascular development
Javerzat, S., Auguste, P., & Bikfalvi, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02394-8 · Cited by 266
Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., Kollmannsberger, C., Rha, S. Y., Bjarnason, G. A., Melichar, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70030-0 · Cited by 262
Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis
Cao, R., Ji, H., Feng, N., Zhang, Y., Yang, X., Andersson, P., Sun, Y., Tritsaris, K., Hansen, A. J., Dissing, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208324109 · Cited by 225
Angiopoietins in tumours: the angiogenic switch
Tait, C. R., & Jones, P. F. (2004) · The Journal of Pathology · doi:10.1002/path.1618 · Cited by 223
R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
Cao, Y., Cao, R., & Hedlund, E.-M. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0337-z · Cited by 215
Schmoll, H.-J., Cunningham, D., Sobrero, A., Karapetis, C. S., Rougier, P., Koski, S. L., Kocakova, I., Bondarenko, I., Bodoky, G., Mainwaring, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5355 · Cited by 213
Xue, Y., Lim, S., Yang, Y., Wang, Z., Jensen, L. D. E., Hedlund, E.-M., Andersson, P., Sasahara, M., Larsson, O., Galter, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2575 · Cited by 212
The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward
Kieran, M. W., Kalluri, R., & Cho, Y.-J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006593 · Cited by 206
Jahangiri, A., De Lay, M., Miller, L. M., Carbonell, W. S., Hu, Y.-L., Lu, K., Tom, M. W., Paquette, J., Tokuyasu, T. A., Tsao, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1281 · Cited by 202
Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy
Gerald, D., Chintharlapalli, S., Augustin, H. G., & Benjamin, L. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4697 · Cited by 202
Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis
Cao, Y. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.002 · Cited by 190
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
You, W.-K., & McDonald, D. M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.12.833 · Cited by 190
Intricacies of Bevacizumab-Induced Toxicities and Their Management
Gressett, S. M., & Shah, S. R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l426 · Cited by 187
Giavazzi, R., Sennino, B., Coltrini, D., Garofalo, A., Dossi, R., Ronca, R., Tosatti, M. P. M., & Presta, M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64325-8 · Cited by 185
Structure and Physiology of the RET Receptor Tyrosine Kinase
Ibanez, C. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009134 · Cited by 183
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
Mross, K., Stefanic, M., Gmehling, D., Frost, A., Baas, F., Unger, C., Strecker, R., Henning, J., Gaschler-Markefski, B., Stopfer, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0694 · Cited by 171
Hoff, P. M., Hochhaus, A., Pestalozzi, B. C., Tebbutt, N. C., Li, J., Kim, T. W., Koynov, K. D., Kurteva, G. P., Pintér, T., Cheng, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6031 · Cited by 165
Wilmes, L. J., Pallavicini, M. G., Fleming, L. M., Gibbs, J., Wang, D., Li, K., Partridge, S. C., Henry, R. G., Shalinsky, D. R., Hu‐Lowe, D. D., et al. (2007) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2006.09.041 · Cited by 157
Griffioen, A. W., Mans, L. A., de Graaf, A. M. A., Nowak-Sliwinska, P. M., de Hoog, C. L. M. M., de Jong, T. A. M., Vyth‐Dreese, F. A., B, J. R. V. B., Bex, A., & Jonasch, E. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0002 · Cited by 156
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
Hamberg, P., Verweij, J., & Sleijfer, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0274 · Cited by 155
Ding, W., Knox, T. R., Tschumper, R. C., Wu, W., Schwager, S. M., Boysen, J. C., Jelinek, D. F., & Kay, N. E. (2010) · Blood · doi:10.1182/blood-2010-02-269894 · Cited by 153
Tejada, M. L., Yu, L., Dong, J., Jung, K., Meng, G., Peale, F. V., Jr., Frantz, G. D., Hall, L., Liang, X., Gerber, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1770 · Cited by 148
Cai, Z., Zhang, Y., Borzilleri, R. M., Qian, L., Barbosa, S. A. L., Wei, D. D., Zheng, X., Wu, L., Fan, J., Shi, Z., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7013309 · Cited by 144
von Minckwitz, G., Puglisi, F., Cortés, J., Vrdoljak, E., Marschner, N. W., Zielinski, C. C., Villanueva, C., Romieu, G., Láng, I., Ciruelos, E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70439-5 · Cited by 143
Demetri, G. D., Garrett, C. R., Schöffski, P., Shah, M. H., Verweij, J., Leyvraz, S., Hurwitz, H. I., Pousa, A. L., Cesne, A. L., Goldstein, D. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3005 · Cited by 140
Wojta, J., Kaun, C., Breuss, J. M., Koshelnick, Y., Beckmann, R., Hattey, E., Mildner, M., Weninger, W., Nakamura, T., Tschachler, E., et al. (1999) · PubMed · Cited by 139
Kim, S., Yazici, Y. D., Calzada, G., Wang, Z.-Y., Younes, M. N., Jasser, S. A., El‐Naggar, A. K., & Myers, J. N. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0595 · Cited by 138
Mackey, J. R., Ramos-Vázquez, M., Lipatov, O. N., McCarthy, N. J., Krasnozhon, D., Семиглазов, В. Ф., Manikhas, A., Gelmon, K. A., Konecny, G. E., Webster, M. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1513 · Cited by 136
Lieu, C. H., Tran, H. T., Jiang, Z.-Q., Mao, M., Overman, M. J., Lin, E. H., Eng, C., Morris, J. S., Ellis, L. M., Heymach, J. V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077117 · Cited by 136
Angevin, E., Lopez-Martin, J. A., Lin, C., Gschwend, J. E., Harzstark, A. L., Castellano, D., Soria, J., Sen, P., Chang, J. E., Shi, M. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2885 · Cited by 135
Gligorov, J., Doval, D., Bines, J., Alba, E., Cortes, P., Pierga, J., Gupta, V. G., Costa, R. D. P., Srock, S., de Ducla, S., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70444-9 · Cited by 133
MET: A Critical Player in Tumorigenesis and Therapeutic Target
Graveel, C. R., Tolbert, D., & Vande Woude, G. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009209 · Cited by 128
Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells
Wu, E., Palmer, N., Tian, Z., Moseman, A. P., Galdzicki, M., Wang, X., Berger, B., Zhang, H., & Kohane, I. S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003794 · Cited by 118
Understanding and targeting resistance to anti-angiogenic therapies.
Clarke, J. M., & Hurwitz, H. I. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.036 · Cited by 109
Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?
Cascone, T., & Heymach, J. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7621 · Cited by 108
Laurie, S. A., Solomon, B., Seymour, L., Ellis, P. M., Goss, G. D., Shepherd, F. A., Boyer, M. J., Arnold, A., Clingan, P. R., Laberge, F., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.032 · Cited by 104
VEGF Trap induces antiglioma effect at different stages of disease
Gomez‐Manzano, C., Holash, J. A., Fueyo-Margareto, J., Xu, J., Conrad, C. A., Aldape, K., de Groot, J. F., Bekele, B. N., & Yung, W. K. A. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-061 · Cited by 103
Ellis, P. M., Kaiser, R., Zhao, Y., Stopfer, P., Gyorffy, S., & Hanna, N. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2944 · Cited by 98
Self-citationPDGF receptor kinase inhibitors for the treatment of PDGF driven diseases
Levitzki, A. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.010 · Cited by 94
Okamoto, I., Kaneda, H., Satoh, T., Okamoto, W., Miyazaki, M., Morinaga, R., Ueda, S., Terashima, M., Tsuya, A., Sarashina, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0379 · Cited by 94
Loupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Desidero, T. D., Canu, B., Schirripa, M., Frumento, P., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.85 · Cited by 89
Vandetanib for the Treatment of Medullary Thyroid Cancer
Chau, N. G., & Haddad, R. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2353 · Cited by 86
Kodama, M., Kitadai, Y., Sumida, T., Ohnishi, M., Ohara, E., Tanaka, M., Shinagawa, K., Tanaka, S., Yasui, W., & Chayama, K. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01639.x · Cited by 83
Hanna, N. H., Kaiser, R., Sullivan, R. N., Aren, O. R., Ahn, M., Tiangco, B., Zvirbule, Z., Barrios, C. H., Demirkazık, A., Gaschler‐Markefski, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8034 · Cited by 83
Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers
Stopfer, P., Rathgen, K., Bischoff, D., Lüdtke, S., Marzin, K., Kaiser, R., Wagner, K., & Ebner, T. (2011) · Xenobiotica · doi:10.3109/00498254.2010.545452 · Cited by 80
Spratlin, J. L. (2011) · Current Oncology Reports · doi:10.1007/s11912-010-0149-5 · Cited by 80
Olson, P., Chu, G. C., Perry, S. R., Nolan-Stevaux, O., & Hanahan, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111079108 · Cited by 79
Doebele, R. C., Conkling, P., Traynor, A. M., Otterson, G. A., Zhao, Y., Wind, S., Stopfer, P., Kaiser, R., & Camidge, D. R. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr596 · Cited by 79
Self-citationTargeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models
Lu, C., Shahzad, M. M. K., Moreno‐Smith, M., Lin, Y. G., Jennings, N. B., Allen, J. K., Landen, C. N., Mangala, L. S., Armaiz-Peña, G. N., Schmandt, R. E., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.3.10635 · Cited by 75
Biomarkers for Anti-Angiogenic Therapy in Cancer
Wehland, M., Bauer, J. W., Magnusson, N. E., Infanger, M., & Grimm, D. G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14059338 · Cited by 74
Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer
Kristensen, T., Knutsson, M., Wehland, M., Laursen, B. E., Grimm, D. G., Warnke, E., & Magnusson, N. E. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151223024 · Cited by 70
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Zhou, J., Goh, B.-C., Albert, D. H., & Chen, C.-S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-33 · Cited by 65
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
Crinò, L., & Metro, G. (2014) · European Respiratory Review · doi:10.1183/09059180.00008913 · Cited by 65
du Bois, A., Huober, J., Stopfer, P., Pfisterer, J., Wimberger, P., Loibl, S., Reichardt, V. L., & Harter, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp506 · Cited by 62
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
Ballas, & Chachoua (2011) · OncoTargets and Therapy · doi:10.2147/ott.s18155 · Cited by 61
Eisen, T. G., Shparyk, Y. V., MacLeod, N. J., Jones, R. J., Wallenstein, G., Temple, G., Khder, Y., Dallinger, C., Studeny, M., Loembé, A., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9962-7 · Cited by 54
Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use
Aprile, G., Bonotto, M., Ongaro, E., Pozzo, C., & Giuliani, F. (2013) · Drugs · doi:10.1007/s40265-013-0154-8 · Cited by 50
Bousquet, G., Alexandre, J., Tourneau, C. L., Goldwasser, F., Faivre, S. J., de Mont-Serrat, H., Kaiser, R., Misset, J. L., & Raymond, É. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.440 · Cited by 47
Majumder, S., Piguet, A.-C., Dufour, J., & Chatterjee, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.026 · Cited by 43
Cediranib: a VEGF Receptor Tyrosine Kinase Inhibitor
Sahade, M., Capareli, F. C., & Hoff, P. M. (2012) · Future Oncology · doi:10.2217/fon.12.73 · Cited by 34
Kudo, K., Arao, T., Tanaka, K., Nagai, T., Furuta, K., Sakai, K., Kaneda, H., Matsumoto, K., Tamura, D., Aomatsu, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2755 · Cited by 33
Cyran, C. C., Kazmierczak, P. M., Hirner, H., Moser, M., Ingrisch, M., Havla, L., Michels, A., Eschbach, R., Schwarz, B., Reiser, M. F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076009 · Cited by 30
Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma
Sonpavde, G., Willey, C. D., & Sudarshan, S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.871259 · Cited by 29
Sun, H., Zhu, M.-S., Wu, W., Shi, X.-D., & Xu, L. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i12.830 · Cited by 29
BIBF 1120 for the treatment of non-small cell lung cancer
Reck, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.488220 · Cited by 14
Cited by
Silver nanoparticles: Synthesis, medical applications and biosafety
Xu, L., Wang, Y.-Y., Huang, J., Chen, C.-Y., Wang, Z.-X., & Xie, H. (2020) · Theranostics · doi:10.7150/thno.45413 · Cited by 1,315
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
The role of microenvironment in tumor angiogenesis
Jiang, X., Wang, J., Deng, X., Xiong, F., Zhang, S., Gong, Z., Li, X., Cao, K., Deng, H., He, Y., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01709-5 · Cited by 761
The Contribution of Angiogenesis to the Process of Metastasis
Bielenberg, D. R., & Zetter, B. R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000138 · Cited by 523
Wang, J., Wang, L., Lou, G.-H., Zeng, H.-R., Hu, J., Huang, Q.-W., Peng, W., & Yang, X.-B. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1577466 · Cited by 424
Metadata
- Authors
- Zhao, Y., & Adjei, A. A.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-22
- Volume
- 20
- Issue
- 6
- Pages
- 660-673
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2161579181
- Cited by
- 558
- References
- 129
- FWCI
- 19.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.